Systematic Reviews and Meta Analysis
BibTex RIS Cite

Effect Of Capd Treatment On Platelet Functıons

Year 1988, Volume: 41 Issue: 2, 243 - 252, 30.06.1988

Oktay Karatan

Abstract

Adenosine diphoshate (ADP) and epinephrine induced platelet aggregations and platelet factor-3 availability were studied in twenty- four patients with end stage renal failure prior t0 and one month la- ter CAPD.
ADP and epinephrine induced aggregation functions were significantly lower (p<0.001) than controls in the patients group prior to CAPD the increase in ADP and epinephrine induced platelet aggregations were found to be significant with CAPD (p<0.001).
Impaired platelet factor-3 availability prior to therapy were improved after CAPD.

Keywords

CAPD renal PLATELET FUNCTIONS

References

  • 1. Akman N,, Ulutin ON. : Üremilerde trombosit fonksiyonları üzerinde in vivo ve in vitro bir çalışma Cerrahpaşa Tıp Bülteni. 3 : 105, 1969.
  • 2. Anagtoston A., Kurtzman NA. : Hematologiceal Conseguences of renal failure. The Kidney (Brenner BM., Rector J. FC, Ed.) 5: 1631-1656, 1985.
  • 3. Bazilinski N., Shaykh M., Dunea, G., Mamdani B., Patel A., Czapek E.,, Ahmed 5.:
  • 4. Inhibition of platelet function by uremic middle Molecules. Nephron 40 : 423, 1985.
  • 5. Berkarda B. : Böbrek yetmezliğinde hemostaz bozuklukları. Hematoloji (İstanbul), 1: 174, 1970.
  • 6. Bertoli M., Gasparotton ML.. Vertolli U., Ruffatti., Landro D.D.. Romagnoli GP. : Does hypercoagulability exist in CAPD patient Periton, Dialys. Bull 4 : 237, 1984.
  • 7. Balard HS., Marcus AJ.: Primary and secondary platelet aggregation in uremia Scand. J Haemet. 9 : 98, 1972. !
  • 8. Bushinsky D.A. : Systemic Conseguences of Chronic Renal Failure Clinical Nephrology (Levine SA., ed) W.B. Saunders Company, philadelphia, 1987, 5. 278- 292,
  • 9. Castaldi PA., Rozenberg MC. Stewart JH. : The bleeding disorder of uremia, of uremia, & gualitative platelet defect. Lancet 11 : 66, 1966.
  • 10. Chapman GV., Ward RA. Farrell PC. : Separation and guantification of the middle molecules in uremia. Kidney int. 17 : 82, 1980.
  • 11. Contreras R., Later R., Navarro J., Touraime JL., Fregria AM, Traeger J.: Molecules in the middie moleçular weight range. Critical review of methods of separation from fluids of uremic patients. Nephron 32 ; 193, 1982,
  • 12. Donner L., Neuwirtova : The hemostatic defect of acute and chronic uremia Thromb Diath Haemoirh 5 : 319, 1960.
  • 13. Gallice P., Fournier N., Crevat A., Sajnera 5. Frayssinet R., Murisasco., Sicardi F. ; In vitro inhibition of platelet aggeregation by uremic middle molecules. Biomedecine 33 : 185, 1980.
  • 14. Hardisty RM., Huton RA. : Platelet Aggregation and availability of platelet factor-3 Brit. J, Haemat. 12 : 764, 1966.
  • 15. Hardisty RM., Huton RA. : The kaolin Clotting time of platelet rich plasma :A test of platelet factor-3 availability. Brit. J Haemat. 11 : 258, 1965.
  • 16. Horowitz HI. Cohen BD., Martiner P., Papayonou MF. : Defective ADP, induced platelet façtor-3 activation in uremia. Blood, 30 : 331, 1967.
  • 17. Horowitz H., Stein IM., Cohen BD., White JG. : Further studies on the platelet inhibiting effect of guanidinosuccinic acid and role in uremiç bleeding Amer. J. Med., 49 : 336, 1970.
  • 18. Karatan O., Tutkak H. Eymir Atilla : Kronik böbrek yetmezliğinde trombosit fonksiyonları. Ankara Tıp Bülteni. 4 : 265, 1982.
  • 19. Lindsay RM. : Practical use of anticoagulants : Replacement of renal function by dialysis (Drukker W.. Parsons FM., Maher JF ed.) Martinus Nighoff Publishers, 1983, 5. 213.
  • 20. Lindsay RM, Fricsen M., Koens F., Linton AL. Oreopoulos DG. de Weber GA. : Platelet function in patients on long term peritoneal dialysis clin Nephrol 6 : 335, 1976.
  • 21. Lindsay RM., Moorthy AV,, Koens F. Linton AL.: Platelet function in dialyzed non dialyzed patients with chronic renal failure Clin. Nephrol. 4 : 52, 1975.
  • 22. Nenci GG., Berrettini M., Agnelli. G,, Parise P., Buongristiani U., Ballatori E : Effect of peritoneal dialysis, haemodialysis and kidney transplantation on blood platelet function 1. platelet aggregation by ADP and epinephrine. Nephron 23 : 287, 1979.
  • 23. Rabien SF : Uremic bleeding. Proc. Hemost Thromb 1 : 233, 1972.
  • 24. Rabiner SF., Drake RF. : Platelet function as an indicator of adeguate dialysis. Kidney int. (Suppl) 2 . 144, 1975.
  • 25. Rabiner SF., Hrodek O. : Platelet factor-3 in normal subjects and patients with renal fajlure J Clin Invest. 47 : 901, 1968.
  • 26. Rabier SF, Molnias F. : The role of phenol and phenolic acuds on defective platelet aggregation of patients with renal failure. Amer. J. Med. 49 : 346, 1970.
  • 27. Sabo AS, Bartoli F.. Castro RA. : In vivo Platelet Hyperreactivity, another Risk Factor for patients under Continous Ambulatory Peritoneal Dialysis. Nephron 29 : 228, 1988.
  • 28. Viener A., Aviram OS, Brook JG., : Enhanced in vilru plalelet Aggregatlon in Hemodialysis Patients. Nephron 43 : 139, 1986.
  • 29. William WJ., Beutler E., Ersley., Rundles R. : Hematology M., Graw Hill book company, 1972 5. 1201-1207.
  • 30. Youdim BMH. : Preparation of human plateletes. Ciba Fouudation Symposium 39 (New series), 5. 405-406, 1976,
  • 31. Zweifler AJ., Sanbar Inhibition of platelet adhesiveness and aggeregâtion by benzi alcohol and phenol. Thrombos Diath. Haemorrh. 21 : 362, 1968,

Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi

Year 1988, Volume: 41 Issue: 2, 243 - 252, 30.06.1988

Oktay Karatan

Abstract

Adenozin difosfat (ADP) ve epinefrin kaynaklı trombosit agregasyonları ve trombosit faktör-3 bulunabilirliği, t0 öncesi ve bir ay sonrası CAPD'li son evre böbrek yetmezliği olan yirmi dört hastada incelendi.
ADP ve epinefrin kaynaklı agregasyon fonksiyonları, CAPD öncesi hasta grubunda kontrollerden önemli ölçüde daha düşüktü (p<0,001) ADP ve epinefrin kaynaklı trombosit agregasyonlarındaki artışın CAPD ile önemli olduğu bulundu (p<0,001).
Terapiden önce bozulmuş trombosit faktör-3 bulunabilirliği, CAPD'den sonra iyileşti.

Keywords

TROMBOSİT FONKSİYONLAR böbrek yetmezliği Adenozin difosfat

References

  • 1. Akman N,, Ulutin ON. : Üremilerde trombosit fonksiyonları üzerinde in vivo ve in vitro bir çalışma Cerrahpaşa Tıp Bülteni. 3 : 105, 1969.
  • 2. Anagtoston A., Kurtzman NA. : Hematologiceal Conseguences of renal failure. The Kidney (Brenner BM., Rector J. FC, Ed.) 5: 1631-1656, 1985.
  • 3. Bazilinski N., Shaykh M., Dunea, G., Mamdani B., Patel A., Czapek E.,, Ahmed 5.:
  • 4. Inhibition of platelet function by uremic middle Molecules. Nephron 40 : 423, 1985.
  • 5. Berkarda B. : Böbrek yetmezliğinde hemostaz bozuklukları. Hematoloji (İstanbul), 1: 174, 1970.
  • 6. Bertoli M., Gasparotton ML.. Vertolli U., Ruffatti., Landro D.D.. Romagnoli GP. : Does hypercoagulability exist in CAPD patient Periton, Dialys. Bull 4 : 237, 1984.
  • 7. Balard HS., Marcus AJ.: Primary and secondary platelet aggregation in uremia Scand. J Haemet. 9 : 98, 1972. !
  • 8. Bushinsky D.A. : Systemic Conseguences of Chronic Renal Failure Clinical Nephrology (Levine SA., ed) W.B. Saunders Company, philadelphia, 1987, 5. 278- 292,
  • 9. Castaldi PA., Rozenberg MC. Stewart JH. : The bleeding disorder of uremia, of uremia, & gualitative platelet defect. Lancet 11 : 66, 1966.
  • 10. Chapman GV., Ward RA. Farrell PC. : Separation and guantification of the middle molecules in uremia. Kidney int. 17 : 82, 1980.
  • 11. Contreras R., Later R., Navarro J., Touraime JL., Fregria AM, Traeger J.: Molecules in the middie moleçular weight range. Critical review of methods of separation from fluids of uremic patients. Nephron 32 ; 193, 1982,
  • 12. Donner L., Neuwirtova : The hemostatic defect of acute and chronic uremia Thromb Diath Haemoirh 5 : 319, 1960.
  • 13. Gallice P., Fournier N., Crevat A., Sajnera 5. Frayssinet R., Murisasco., Sicardi F. ; In vitro inhibition of platelet aggeregation by uremic middle molecules. Biomedecine 33 : 185, 1980.
  • 14. Hardisty RM., Huton RA. : Platelet Aggregation and availability of platelet factor-3 Brit. J, Haemat. 12 : 764, 1966.
  • 15. Hardisty RM., Huton RA. : The kaolin Clotting time of platelet rich plasma :A test of platelet factor-3 availability. Brit. J Haemat. 11 : 258, 1965.
  • 16. Horowitz HI. Cohen BD., Martiner P., Papayonou MF. : Defective ADP, induced platelet façtor-3 activation in uremia. Blood, 30 : 331, 1967.
  • 17. Horowitz H., Stein IM., Cohen BD., White JG. : Further studies on the platelet inhibiting effect of guanidinosuccinic acid and role in uremiç bleeding Amer. J. Med., 49 : 336, 1970.
  • 18. Karatan O., Tutkak H. Eymir Atilla : Kronik böbrek yetmezliğinde trombosit fonksiyonları. Ankara Tıp Bülteni. 4 : 265, 1982.
  • 19. Lindsay RM. : Practical use of anticoagulants : Replacement of renal function by dialysis (Drukker W.. Parsons FM., Maher JF ed.) Martinus Nighoff Publishers, 1983, 5. 213.
  • 20. Lindsay RM, Fricsen M., Koens F., Linton AL. Oreopoulos DG. de Weber GA. : Platelet function in patients on long term peritoneal dialysis clin Nephrol 6 : 335, 1976.
  • 21. Lindsay RM., Moorthy AV,, Koens F. Linton AL.: Platelet function in dialyzed non dialyzed patients with chronic renal failure Clin. Nephrol. 4 : 52, 1975.
  • 22. Nenci GG., Berrettini M., Agnelli. G,, Parise P., Buongristiani U., Ballatori E : Effect of peritoneal dialysis, haemodialysis and kidney transplantation on blood platelet function 1. platelet aggregation by ADP and epinephrine. Nephron 23 : 287, 1979.
  • 23. Rabien SF : Uremic bleeding. Proc. Hemost Thromb 1 : 233, 1972.
  • 24. Rabiner SF., Drake RF. : Platelet function as an indicator of adeguate dialysis. Kidney int. (Suppl) 2 . 144, 1975.
  • 25. Rabiner SF., Hrodek O. : Platelet factor-3 in normal subjects and patients with renal fajlure J Clin Invest. 47 : 901, 1968.
  • 26. Rabier SF, Molnias F. : The role of phenol and phenolic acuds on defective platelet aggregation of patients with renal failure. Amer. J. Med. 49 : 346, 1970.
  • 27. Sabo AS, Bartoli F.. Castro RA. : In vivo Platelet Hyperreactivity, another Risk Factor for patients under Continous Ambulatory Peritoneal Dialysis. Nephron 29 : 228, 1988.
  • 28. Viener A., Aviram OS, Brook JG., : Enhanced in vilru plalelet Aggregatlon in Hemodialysis Patients. Nephron 43 : 139, 1986.
  • 29. William WJ., Beutler E., Ersley., Rundles R. : Hematology M., Graw Hill book company, 1972 5. 1201-1207.
  • 30. Youdim BMH. : Preparation of human plateletes. Ciba Fouudation Symposium 39 (New series), 5. 405-406, 1976,
  • 31. Zweifler AJ., Sanbar Inhibition of platelet adhesiveness and aggeregâtion by benzi alcohol and phenol. Thrombos Diath. Haemorrh. 21 : 362, 1968,
There are 31 citations in total.

Details

Primary Language Turkish
Subjects Pediatric Nephrology
Journal Section Articles
Authors

Oktay Karatan This is me

Publication Date June 30, 1988
Published in Issue Year 1988 Volume: 41 Issue: 2

Cite

APA Karatan, O. (1988). Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi. Ankara Üniversitesi Tıp Fakültesi Mecmuası, 41(2), 243-252.
AMA Karatan O. Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi. Ankara Üniversitesi Tıp Fakültesi Mecmuası. June 1988;41(2):243-252.
Chicago Karatan, Oktay. “Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 41, no. 2 (June 1988): 243-52.
EndNote Karatan O (June 1, 1988) Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi. Ankara Üniversitesi Tıp Fakültesi Mecmuası 41 2 243–252.
IEEE O. Karatan, “Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi”, Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol. 41, no. 2, pp. 243–252, 1988.
ISNAD Karatan, Oktay. “Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 41/2 (June1988), 243-252.
JAMA Karatan O. Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 1988;41:243–252.
MLA Karatan, Oktay. “Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi”. Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol. 41, no. 2, 1988, pp. 243-52.
Vancouver Karatan O. Capd Tedavisinin Trombosit Fonksiyonlarına Etkisi. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 1988;41(2):243-52.
 Download Cover Image